Lead Sponsor

Pfizer

Age

21 - 70 years

Sex

ALL

Healthy Volunteers

No

•Male and/or female subjects between the ages of 21 to 70 who have a clinical diagnosis of either discoid cutaneous lupus erythematosus or subacute cutaneous lupus erythematosus with or without systemic lupus erythematosus prior to screening that has been confirmed by evaluation of skin biopsy sample.
•Active disease at both screening and baseline (Day 1) defined by a CLASI score of greater than or equal to 10.
•Intolerance to antimalarial therapy or more than 3 months of antimalarial therapy with disease activity.

•Use of greater than or equal to 20 mg or prednisone (or equivalent) within 3 months of Day 1.
•Signs or symptoms or relevant history of a viral, bacterial, fungal, and parasitic infection, or recent history of repeated infections
•Subjects with evidence of past or active tuberculosis
•Pregnant, planning to get pregnant, and/or lactating females or males planning to father a child within time period of the study or subsequent exclusionary period.

Related studies

NCT06875960 · Systemic Lupus Erythematosus (SLE), Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)

NCT06927219 · Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN), and more

NCT07072611 · Cutaneous Lupus Erythematosus

NCT05411016 · Healthy Volunteers, Systemic Lupus Erythematosus (SLE), and more

NCT05629208 · Cutaneous Lupus Erythematosus (CLE)

A Multiple Dose Study Of PD-0360324 In Patients With Active Cutaneous Lupus Erythematosus